| Metric | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Total revenue | $19.5M+77.1% | $11.0M | $0 | $0 |
| Selling, general and administrative | $115.7M+17.8% | $98.2M+54.6% | $63.5M+292.5% | $16.2M |
| Research and development | $13.7M-59.7% | $33.9M-18.1% | $41.4M+7093.1% | $576K |
| Amortization of acquired intangible assets | $25.9M+18.9% | $21.8M+290.3% | $5.6M | $0 |
| Gain on sale of Theravance Respiratory Company, LLC ("TRC") | $0 | $0+100.0% | -$266.7M | $0 |
| Loss on extinguishment of debt | $0 | $0-100.0% | $20.7M | $0 |
| Changes in fair values of equity method investments, net | $64.3M+183.0% | -$77.4M-147.8% | $161.7M+291.7% | -$84.4M |
| Changes in fair value of equity and long-term investments, net | $59.2M+631.6% | -$11.1M-31.5% | -$8.5M-27.5% | -$6.6M |
| Interest and dividend income | -$19.1M-21.0% | -$15.8M-148.4% | -$6.4M-246.3% | -$1.8M |
| Interest expense | $22.2M+15.9% | $19.2M+21.3% | $15.8M-17.2% | $19.1M |
| Other expense, net | $3.0M-39.7% | $5.0M+47.3% | $3.4M-7.0% | $3.6M |
| Total expenses, net | $321.3M+176.1% | $116.4M+162.1% | $44.4M+183.1% | -$53.4M |
| Income before income taxes | $37.4M-80.7% | $194.1M-32.4% | $286.9M-35.6% | $445.3M |
| Income tax expense, net | $14.0M-2.6% | $14.4M-78.4% | $66.7M-12.8% | $76.4M |
| Net income | $23.4M-87.0% | $179.7M-18.4% | $220.3M-40.3% | $368.8M |
| Net loss attributable to noncontrolling interests | $0 | $0-100.0% | $6.3M-93.8% | $103.0M |
| Net income attributable to Innoviva stockholders | $23.4M-87.0% | $179.7M-16.0% | $213.9M-19.5% | $265.9M |
| Basic net income per share attributable to Innoviva stockholders | $370.00-86.5% | $2750.00-10.4% | $3070.00-5.2% | $3240.00 |
| Diluted net income per share attributable to Innoviva stockholders | $360.00-83.6% | $2200.00-7.2% | $2370.00-17.4% | $2870.00 |
| Shares used to compute basic net income per share | $62726000.00-4.1% | $65435000.00-6.0% | $69644000.00-15.1% | $82062000.00 |
| Shares used to compute diluted net income per share | $74187000.00-14.6% | $86876000.00-8.8% | $95248000.00+1.0% | $94310000.00 |
| Royalty revenue | ||||
| Net product sales | ||||
| Cost of products sold (inclusive of amortization of inventory fair value adjustments, excluding amortization of intangible assets) | $36.6M-10.8% | $41.0M+197.5% | $13.8M | $0 |
| License and other revenue | ||||
| License | ||||
| Cost of license revenue | $0-100.0% | $1.6M | $0 | $0 |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.